Home › Funds › ACT CAPITAL MANAGEMENT, LLC › VIR
ACT CAPITAL MANAGEMENT, LLC position in VIR
VIR BIOTECHNOLOGY INC · Health Care
ACT CAPITAL MANAGEMENT, LLC reported holding 64,300 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q2 2026 13F filing — a position valued at US$655K, representing 0.43% of its reported portfolio and ranking #34 among its reported holdings. ACT CAPITAL MANAGEMENT, LLC has disclosed VIR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACT CAPITAL MANAGEMENT, LLC's VIR position evolved
ACT CAPITAL MANAGEMENT, LLC first disclosed a stake in VIR in Q1 2026 at 64,300 shares (US$576K). The position peaked in Q2 2026 at 64,300 shares, worth US$655K. Across 2 filings, ACT CAPITAL MANAGEMENT, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 64,300 shares valued at US$655K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 64.30K | $576.13K | New |
| Q2 2026 | 64.30K | $655.22K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VIR and 13F data
VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 50 other funds we track also report a position in VIR — the largest reported positions include ARCH Venture Management, LLC (US$129.4M), SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), GSK plc (US$87.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VIR
- ARCH Venture Management, LLC 12.69M sh · $129.35M · Q2 2026
- SB INVESTMENT ADVISERS (UK) LTD 10.95M sh · $111.56M · Q2 2026
- GSK plc 8.55M sh · $87.13M · Q2 2026
- ADAR1 Capital Management, LLC 2.46M sh · $25.03M · Q2 2026
- Boxer Capital Management, LLC 1.87M sh · $19.01M · Q2 2026
- GordonMD Global Investments LP 1.35M sh · $13.79M · Q2 2026
- Sio Capital Management, LLC 1.08M sh · $10.96M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 853.68K sh · $8.70M · Q2 2026
- Saturn V Capital Management LP 770.64K sh · $7.85M · Q2 2026
- Jones Hill Capital LP 659.21K sh · $6.72M · Q2 2026
- Avidity Partners Management LP 519.30K sh · $5.29M · Q2 2026
- Alta Partners Management Company, L.P. 509.92K sh · $5.20M · Q2 2026
More on ACT CAPITAL MANAGEMENT, LLC
FAQ
How long has ACT CAPITAL MANAGEMENT, LLC held VIR?
ACT CAPITAL MANAGEMENT, LLC has disclosed VIR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ACT CAPITAL MANAGEMENT, LLC's current position in VIR?
As of Q2 2026, ACT CAPITAL MANAGEMENT, LLC holds 64.30K shares of VIR (VIR BIOTECHNOLOGY INC), valued at $655.22K, representing 0.43% of its reported portfolio and ranking #34.
Has ACT CAPITAL MANAGEMENT, LLC been buying or selling VIR?
In the latest 13F filing (Q2 2026), ACT CAPITAL MANAGEMENT, LLC held unchanged its position in VIR. The position peaked in Q2 2026 at 64.30K shares.
Which other funds hold VIR?
Other major institutional holders of VIR include ARCH Venture Management, LLC, SB INVESTMENT ADVISERS (UK) LTD, GSK plc, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.